Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 83 Breast Neoplasms 60 Prostatic Neoplasms 30 Triple Negative Breast Neoplasms 26 Neoplasms 24 Fallopian Tube Neoplasms 22 Neoplasm Metastasis 18 Pancreatic Neoplasms 17 Endometrial Neoplasms 17 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 10 Sarcoma 9 Carcinoma, Non-Small-Cell Lung 9 Stomach Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Recurrence 8 Lung Neoplasms 7 Glioma 7 Fanconi Anemia, Complementation Group D1 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Glioblastoma 6 Colorectal Neoplasms 6 Lymphoma, Non-Hodgkin 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Solid Tumors 4 Neuroendocrine Tumors 4 Metastatic Castration-resistant Prostate Cancer 4 Carcinoma, Squamous Cell 4 Advanced Solid Tumors 4

Interventions

pembrolizumab 268 Nivolumab 241 Ipilimumab 221 aldesleukin 126 Cyclophosphamide 126 Interleukin-2 93 trametinib 76 dabrafenib 68 Dacarbazine 68 Temozolomide 66 fludarabine 64 Vemurafenib 64 fludarabine phosphate 56 Biopsy 45 Radiosurgery 43 sargramostim 40 Bevacizumab 40 binimetinib 39 incomplete Freund's adjuvant 37 Paclitaxel 35 atezolizumab 34 Radiotherapy 34 Cisplatin 34 Blood Specimen Collection 33 encorafenib 32 Magnetic Resonance Spectroscopy 32 cobimetinib 31 Specimen Handling 31 Introns 31 Carboplatin 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05482074 2024-01-19

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡